Antibody Fc engineering plays a crucial role in enhancing natural killer (NK) cell-mediated cytotoxicity. By modifying the fragment crystallizable (Fc) region of monoclonal antibodies (mAbs), such as HuM195 targeting CD33, researchers have developed more effective therapeutic strategies for acute myeloid leukemia (AML) treatment. The introduction of the triple mutation Ser293Asp/Ala330Leu/Ile332Glu (DLE) into the Fc region of HuM195 has shown promising results in improving NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC).
Therapeutic monoclonal antibodies primarily target tumor antigens to induce potent cytotoxicity through effector-mediated functions like ADCC. Fc-engineered mAbs have shown increased affinity for activating receptors, leading to enhanced ADCC and improved clinical outcomes in targeting various antigens like CD19, CD20, Her2, or CD40. NK cells, with their role in ADCC via the CD16 receptor, are pivotal in these antibody-based therapies. Studies have shown a direct link between activating Fc receptors and the efficacy of mAb therapy, emphasizing the importance of NK cells in ADCC.
AML, a common adult leukemia, has been primarily targeted using mAbs directed at CD33. While previous therapies like gemtuzumab ozogamicin showed promise but were later withdrawn due to toxicities, recent data have reignited interest in anti-CD33 antibodies. Fc engineering offers a potential strategy to enhance the effector functions of these antibodies, thereby improving clinical efficacy in AML treatment.
The mechanistic basis of how Fc engineering improves ADCC by NK cells is not fully understood. By utilizing dynamic imaging systems like Time-lapse Imaging Microscopy in Nanowell Grids (TIMING), researchers have been able to analyze the kinetics of thousands of individual NK cells interacting with mAb-coated target cells. This technology has provided insights into how Fc-engineered mAbs promote superior activation of NK cells, leading to enhanced ADCC and rapid target cell apoptosis.
Fc engineering not only increases the quality and quantity of NK cell-mediated ADCC but also promotes serial killing of target cells. DLE-HuM195 has shown to increase the frequency of NK cells inducing apoptosis in multiple target cells, demonstrating its potential for kinetic boosting of cytotoxic responses. These findings have significant implications for improving the therapeutic efficacy of mAbs in cancer treatment, particularly in diseases like AML where enhanced cytotoxicity is crucial for tumor elimination.
Key Takeaways:
– Antibody Fc engineering, such as the DLE mutation in HuM195, enhances NK cell-mediated ADCC and promotes serial killing of target cells.
– Dynamic imaging technologies like TIMING provide valuable insights into the kinetics of NK cell interactions with mAb-coated target cells.
– Improved activation of NK cells through Fc engineering accelerates target cell apoptosis and boosts the efficiency of cytotoxic responses.
– Fc-engineered mAbs hold promise for advancing antibody-based therapies in cancer treatment, with implications for enhancing the efficacy of anti-tumor antibodies, especially in AML therapy.
Tags: downstream, clinical trials, cell therapy, monoclonal antibodies, chromatography
Read more on pmc.ncbi.nlm.nih.gov